Subtype
Lung Neuroendocrine Carcinoma
CI-CAN-00003107Explore in graph →
389 active trials6 approved drugs6 evidence items
- NCIt
- C45569
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003107Explore in graph →
Clinical trials
1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00065429 | Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 64 | ImmunoGen, Inc.INDUSTRY | 1 | Jul 18, 2012 | clinicaltrials |
| NCT00698516 | Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer | completed | Phase 2 | 50 | GlaxoSmithKlineINDUSTRY | 1 | Mar 27, 2012 | clinicaltrials |
| NCT00046787 |
| Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer |
| completed |
| Phase 2 |
| 47 |
| Astellas Pharma IncINDUSTRY |
| 2 |
| Oct 20, 2011 |
| clinicaltrials |
| NCT00317200 | A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer | completed | Phase 2 | 34 | Hoosier Cancer Research NetworkOTHER | 1 | May 2, 2011 | clinicaltrials |
| NCT00403403 | A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE) | completed | Phase 2 | 102 | Genentech, Inc.INDUSTRY | 0 | Apr 29, 2011 | clinicaltrials |
| NCT00156286 | Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC | completed | Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 16, 2010 | clinicaltrials |
| NCT01222936 | LBH Phase II in Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 21 | Southern Europe New Drug OrganizationOTHER | 2 | Oct 18, 2010 | clinicaltrials |
| NCT00397293 | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Ascenta TherapeuticsINDUSTRY | 3 | Aug 24, 2010 | clinicaltrials |
| NCT00294931 | Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 50 | SCRI Development Innovations, LLCOTHER | 1 | Jun 28, 2010 | clinicaltrials |
| NCT00308529 | Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer | completed | Phase 2 | 55 | SCRI Development Innovations, LLCOTHER | 1 | Jun 22, 2010 | clinicaltrials |
| NCT00319969 | Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. | completed | Phase 2 | 76 | Celgene CorporationINDUSTRY | 1 | Sep 30, 2009 | clinicaltrials |
| NCT00116610 | Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer | completed | Phase 2 | 75 | Poniard PharmaceuticalsINDUSTRY | 3 | Jan 21, 2009 | clinicaltrials |
| NCT00290953 | Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide(SESAME) | completed | Phase 2 / Phase 3 | 432 | SanofiINDUSTRY | 14 | Dec 23, 2008 | clinicaltrials |
| NCT00298688 | A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer | completed | Phase 2 | 56 | AstraZenecaINDUSTRY | 2 | Jun 12, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Jul 18, 2012source: clinicaltrials